refine your search for acceleron refine moreformatformat all listings  current page auction buy it now classified ads sort best match best match time ending soonest time newly listed price  shipping lowest first price  shipping highest first distance nearest first view list gallery view customize  results for acceleron follow acceleron to get email alerts and updates on your ebay feed unfollow acceleron to stop getting updates on your ebay feed yay youre now following acceleron in your ebay feedyou will receive email alerts for new listings dont send me email alerts follow this search acceleron   did you mean celeron  items items in search results hot wheels  acceleracers acceleron spine buster   buy it now free shipping fast n free get it on or before fri jul  hot wheels acceleracers  acceleron hollowback   buy it now free shipping fast n free get it on or before fri jul  hot wheels  acceleracers acceleron series spine buster  was previous price  buy it now free shipping only  left  watching  off fast n free get it on or before fri jul  hot wheels acceleracers hollowback orange metal maniacs acceleron series   bids hot wheels  acceleracers acceleron series hollowback  was previous price  buy it now free shipping  off fast n free get it on or before fri jul  hot wheels acceleracers covelight acceleron series  or best offer free shipping see more like thishot wheels acceleracers covelight acceleron series hot wheels acceleracers acceleron series orange metal maniacs hollowback  buy it now hot wheels  acceleracers acceleron series spine buster  buy it now free shipping hot wheels acceleracers spine buster acceleron series  or best offer free shipping see more like thishot wheels acceleracers spine buster acceleron series results matching fewer words unequal halo protective headgear size lxl mm new in box  black    bids new bodyguardz unequal shock protection case for iphone s  buy it now free shipping bodyguardz shock case unequal technology iphone  plus s plus  pink brand new  buy it now free shipping  sold see more like thisbodyguardz shock case unequal technology iphone  plus s plus  pink brand new bodyguardz case unequal technology for iphone  plus  s plus  clearblack  buy it now free shipping see more like thisbodyguardz case unequal technology for iphone  plus  s plus  clearblack new in box bodyguardz shock case with unequals technology for iphone  samsung  buy it now free shipping see more like thisnew in box bodyguardz shock case with unequals technology for iphone  samsung new bodyguardz shock case with unequal technology samsung galaxy s edge gray  buy it now free shipping only  left  watching see more like thisnew bodyguardz shock case with unequal technology samsung galaxy s edge gray new bodyguardz contact case unequal technology samsung galaxy s edge blk clear  buy it now free shipping see more like thisnew bodyguardz contact case unequal technology samsung galaxy s edge blk clear bodyguardz case unequal technology for iphone s  funda  blue  or best offer bodyguardz shock case with unequal technology for apple iphone  plus  s pl  list price previous price  buy it now free shipping see more like thisbodyguardz shock case with unequal technology for apple iphone  plus  s pl free fast shipping bodyguardz shock case unequal technology iphone  pink  screen protector new  buy it now free shipping see more like thisbodyguardz shock case unequal technology iphone  pink  screen protector new new authentic oem bodyguradz iphone  and iphone s pink shock case with unequal  list price previous price  or best offer free shipping see more like thisnew authentic oem bodyguradz iphone  and iphone s pink shock case with unequal bodyguardz case unequal technology for iphone s  funda  pink  or best offer new oem in box bodyguradz iphone  plus  s plus pink shock case with unequal  list price previous price  or best offer free shipping see more like thisnew oem in box bodyguradz iphone  plus  s plus pink shock case with unequal bodyguardz shock case with unequal technology for samsung galaxy s edge pink  buy it now free shipping shock case with unequal technology for apple iphone  plus  s plus  retail  buy it now free shipping see more like thisshock case with unequal technology for apple iphone  plus  s plus  retail new authentic oem bodyguradz blue iphone  and iphone s shock case with unequal  list price previous price  or best offer free shipping see more like thisnew authentic oem bodyguradz blue iphone  and iphone s shock case with unequal new bodyguardz unequal shock protection case for iphone s plus  black  buy it now free shipping see more like thisnew bodyguardz unequal shock protection case for iphone s plus  black bodyguardz shock case with unequal technology for apple iphone   s  pink  buy it now free shipping see more like thisbodyguardz shock case with unequal technology for apple iphone   s  pink new bodyguardz shock case contact for samsung galaxy s edge  black  buy it now free shipping see more like thisnew bodyguardz shock case contact for samsung galaxy s edge  black new in box bodyguardz contact case for samsung s  buy it now free shipping see more like thisnew in box bodyguardz contact case for samsung s bodyguardz contact case w unequal technology samsung galaxy s edgeblacknew  or best offer free shipping wnew bodyguardz unequal impact protection contact case galaxy s active clear  buy it now free shipping only  left  sold see more like thiswnew bodyguardz unequal impact protection contact case galaxy s active clear bodyguardz shock™ case with unequal technology for samsung galaxy sgreynib  or best offer free shipping bodyguardz shock case unequal technology for iphone  plus  s plus  pink  buy it now free shipping see more like thisbodyguardz shock case unequal technology for iphone  plus  s plus  pink bodyguardz unequal impact protection contact case iphone  plus s plus black  buy it now free shipping  sold see more like thisbodyguardz unequal impact protection contact case iphone  plus s plus black bodyguardz  shock case for galaxy s edge plus tpu case with impactabsorbin  buy it now free shipping free fast shipping new bodyguardz shock case with unequal technology samsung galaxy s edge gray  buy it now free shipping see more like thisnew bodyguardz shock case with unequal technology samsung galaxy s edge gray new bodyguardz shock case contact for apple iphone  plus  s plus  pink clear  buy it now free shipping  sold see more like thisnew bodyguardz shock case contact for apple iphone  plus  s plus  pink clear bodyguardz unequal shock case for iphone  black tu  buy it now free shipping bodyguardz  shock case for iphone  plus tpu case with impactabsorbing tech  or best offer free shipping bodyguardz unequal impact protection contact case galaxy s clear  black new  buy it now free shipping tell us what you think ebay determines this price through a machine learned model of the products sale prices within the last  days ebay determines trending price through a machine learned model of the product’s sale prices within the last  days new refers to a brandnew unused unopened undamaged item and used refers to an item that has been used previously top rated plussellers with highest buyer ratingsreturns money backships in a business day with trackinglearn more top rated plussellers with highest buyer ratingsreturns money backships in a business day with trackinglearn more not finding what youre looking forfollow acceleron to get email alerts and updates on your ebay feed search refinements categories all toys  hobbies  contemporary diecast cars trucks  vans  condition see allcondition new  used  price please enter a minimum andor maximum price before continuing  enter minimum price to  enter maximum price format see allformat all listingsfilter applied  auction  buy it now  item location see allitem location defaultfilter applied within within  miles miles miles miles miles miles miles miles miles miles miles miles miles miles miles of enter your zip code  go please enter a valid zipcode us only north america worldwide see allsellerseller delivery options see alldelivery options free shipping free instore pickup show only see allshow only returns accepted completed listings sold listings deals  savings more refinements learn about pricing this page was last updated  jul  number of bids and bid amounts may be slightly out of date see each listing for international shipping options and costs acceleron pharma xlrn  stock predictions  price targets facebook autocomplete demo post a rating  month price target   home trending sign up log in acceleron pharma inc xlrn  last  days median target price   upside positive ratings  of  analysts latest  piper jaffray  overweight     view all analyst ratings for xlrn » facebook autocomplete demo post a rating  month price target   home trending sign up log in analyst ranking   name measured ratings sucess rate avg return  mizuho      credit suisse      jefferies      cantor fitzgerald      bank of america merrill lynch      jmp securities      goldman sachs      raymond james      fbr capital markets      william blair     flashratings  contact us facebook autocomplete demo post a rating  month price target   trending sign up log in contact flashratings your emotional state excited confused worried upset panicked angry flashratings  about us facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings  all research for my stocks the most comprehensive equity research coverage available online never miss a single piece of research upgrade downgrade or target price change by any analyst firm on any stock equity research by professional analysts  especially their rationales more than their forecasts  contains far more interesting and important information about the actual fundamentals of the traded companies than can be gathered from conventional news reports our mission is to unlock access to valuable research on stocks for all retail investors professionals institutions take advantage of our costeffective subscriptions to have flashratingss comprehensive realtime feed delivered into your intranet and trading floor platforms institutional subscriptions websites become a content licensing partner and display flashratingss popular news feed on your website content licensing advertisers advertise with us and have flashratings readers with attractive demographics take advantage of your products advertising flashratings  principles facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings principles  flashratings mission is to provide you  the investor  with as much honest and professional research on your investments as possible  we believe its much better to get a multitude of credible opinions on an investment than to arbitrarily follow any single advisor  be it your banker a friend or a tv pundit  flashratings does not provide advice our job is to accurately and objectively report on analysts credible research and opinions the only advice flashratings will ever give you is to absorb as much fundamental research and different opinions as possible and make your own decisions  flashratings favors covering analysts with proven track records but will cover all analysts as long as their research is honest and professional sign up » acceleron pharma  wikipedia acceleron pharma from wikipedia the free encyclopedia jump to navigation search acceleron pharma inc traded as nasdaq xlrn industry biotechnology founded   headquarters cambridge massachusetts united states key people habib dable ceo steve ertel coo matt sherman cmo kevin mclaughlin cfo  website acceleronpharmacom acceleron pharma inc is a public american clinical stage biopharmaceutical company based in boston massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta tgfβ superfamily of proteins which play fundamental roles in the growth and repair of cells and tissues such as red blood cells muscle bone and blood vessels pipelineedit acceleron has four drugs in clinical trials and one in preclinical development luspatercept ace for anemia  sotatercept ace for kidney disease dalantercept ace for kidney cancer ace for muscular disorders ace historyedit the company was formed in june  in cambridge massachusetts as a delaware corporation the original name was phoenix pharma the founders were scientists jasbir seehra tom maniatis mark ptashne wylie vale and scientific advisor joan massague and business people and investors john knopf and christoph westphal of polaris venture partners who served as founding ceo the company was founded to discover and develop drugs based on the scientific discoveries of the scientific founders in the field of growth factors and transforming growth factors in the fields of metabolic disorders like obesity diabetes osteoporosis and musclewasting conditions the company began with a seed round from polaris of  and then had a series a venture capital investment of  million that it used to open its first laboratory in december  glenn batchelder was appointed president and ceo in june  it started its first clinical trial in june  the product was ace which eventually was named sotatercept a protein therapeutic that was an activin type  receptor antagonist intended to treat bone loss ace was a chimeric protein created by fusing the binding portion of the activin type  receptor to part of an antibody the resulting protein binds to activin and prevents it from acting a muscular belgian blue cow knopf took over as ceo in  he became known for showing pictures of a belgian blue cow to potential inventors as a way of illustrating the companys products potential to develop muscle in  acceleron and celgene started a partnership to jointly develop and market ace in which celgene paid acceleron  million up front and bought  million of acceleron stock and agreed to buy  million more in stock if acceleron went public and agreed to pay up to  million in milestones in a separate deal done at the same time celgene acquired an option to license three products in accelerons pipeline directed to cancer and cancerrelated bone loss in  acceleron extended its their partnership with celgene to include ace a development candidate for anemia celgene paid  million upfront with potential downstream payments of  million in milestones and royalties over  the company held its initial public offering in september  at that time the company had three protein therapeutic candidates being studied in  phase  clinical trials including sotatercept and luspatercept ace which promoted red blood cell production and were being tested as potential treatments for anemia in people with thalassemia and myelodysplastic syndromes mds its other candidate was dalantercept ace an angiogenesis inhibitor as a potential cancer drug in september  knopf retired and the company hired habib dable as ceo at that time the companys lead product luspatercept was in phase iii testing for mds and betathalassemia referencesedit  httpwwwacceleronpharmacomourcompanymanagement  httpwwwacceleronpharmacomproducts  a b luspatercept adisinsight retrieved  february    a b sotatercept adisinsight retrieved  february    a b dalantercept adisinsight retrieved  february    ace  adisinsight retrieved  february    ace  product profile biocentury retrieved  february    a b c cooke philip ed  local clusters and global networks regional knowledge economies google ebook new horizons in regional science united kingdom edward elgar publishing p  isbn    a b mclellan dennis january   wylie w vale jr dies at  researcher helped discover stress hormone los angeles times   a b c d acceleron s acceleron via sec edgar august     acceleron pharma developing drugs to treat musculoskeletal and metabolic disorders secures  million in series a funding nasdaqxlrn investoracceleronpharmacom february     press release acceleron pharma announces departure of jasbir seehra phd chief scientific officer acceleron via fiercebiotech november     press release acceleron pharma appoints glenn batchelder as ceo and adds richard f pops to board of directors acceleron via businesswire june     flanagan michael july   acceleron value in the wallflower biocentury   carroll john november   emerging drug developer acceleron fiercebiotech   heuser stephen july   superbuff cattle may hold key to treating muscular diseases boston globe   celgene commits b to acceleron fiercebiotech february     a b accelerons celgene deal worth almost b boston business journal february     weintraub arlene  august  acceleron gets  million in partnership deal with celgene xconomy   huggett brady december  burning bright nature biotechnology   pp –   lawrence stacy september   bayer commercial vet heads to acceleron as it preps for phiii celgene data fiercebiotech  retrieved from httpsenwikipediaorgwindexphptitleacceleronpharmaoldid categories pharmaceutical companies established in companies based in bostonpharmaceutical companies of the united statescompanies listed on nasdaq establishments in massachusettshealth care companies based in massachusetts navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages deutsch edit links this page was last edited on  june  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view acceleron pharma  wikipedia acceleron pharma from wikipedia the free encyclopedia jump to navigation search acceleron pharma inc traded as nasdaq xlrn industry biotechnology founded   headquarters cambridge massachusetts united states key people habib dable ceo steve ertel coo matt sherman cmo kevin mclaughlin cfo  website acceleronpharmacom acceleron pharma inc is a public american clinical stage biopharmaceutical company based in boston massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta tgfβ superfamily of proteins which play fundamental roles in the growth and repair of cells and tissues such as red blood cells muscle bone and blood vessels pipelineedit acceleron has four drugs in clinical trials and one in preclinical development luspatercept ace for anemia  sotatercept ace for kidney disease dalantercept ace for kidney cancer ace for muscular disorders ace historyedit the company was formed in june  in cambridge massachusetts as a delaware corporation the original name was phoenix pharma the founders were scientists jasbir seehra tom maniatis mark ptashne wylie vale and scientific advisor joan massague and business people and investors john knopf and christoph westphal of polaris venture partners who served as founding ceo the company was founded to discover and develop drugs based on the scientific discoveries of the scientific founders in the field of growth factors and transforming growth factors in the fields of metabolic disorders like obesity diabetes osteoporosis and musclewasting conditions the company began with a seed round from polaris of  and then had a series a venture capital investment of  million that it used to open its first laboratory in december  glenn batchelder was appointed president and ceo in june  it started its first clinical trial in june  the product was ace which eventually was named sotatercept a protein therapeutic that was an activin type  receptor antagonist intended to treat bone loss ace was a chimeric protein created by fusing the binding portion of the activin type  receptor to part of an antibody the resulting protein binds to activin and prevents it from acting a muscular belgian blue cow knopf took over as ceo in  he became known for showing pictures of a belgian blue cow to potential inventors as a way of illustrating the companys products potential to develop muscle in  acceleron and celgene started a partnership to jointly develop and market ace in which celgene paid acceleron  million up front and bought  million of acceleron stock and agreed to buy  million more in stock if acceleron went public and agreed to pay up to  million in milestones in a separate deal done at the same time celgene acquired an option to license three products in accelerons pipeline directed to cancer and cancerrelated bone loss in  acceleron extended its their partnership with celgene to include ace a development candidate for anemia celgene paid  million upfront with potential downstream payments of  million in milestones and royalties over  the company held its initial public offering in september  at that time the company had three protein therapeutic candidates being studied in  phase  clinical trials including sotatercept and luspatercept ace which promoted red blood cell production and were being tested as potential treatments for anemia in people with thalassemia and myelodysplastic syndromes mds its other candidate was dalantercept ace an angiogenesis inhibitor as a potential cancer drug in september  knopf retired and the company hired habib dable as ceo at that time the companys lead product luspatercept was in phase iii testing for mds and betathalassemia referencesedit  httpwwwacceleronpharmacomourcompanymanagement  httpwwwacceleronpharmacomproducts  a b luspatercept adisinsight retrieved  february    a b sotatercept adisinsight retrieved  february    a b dalantercept adisinsight retrieved  february    ace  adisinsight retrieved  february    ace  product profile biocentury retrieved  february    a b c cooke philip ed  local clusters and global networks regional knowledge economies google ebook new horizons in regional science united kingdom edward elgar publishing p  isbn    a b mclellan dennis january   wylie w vale jr dies at  researcher helped discover stress hormone los angeles times   a b c d acceleron s acceleron via sec edgar august     acceleron pharma developing drugs to treat musculoskeletal and metabolic disorders secures  million in series a funding nasdaqxlrn investoracceleronpharmacom february     press release acceleron pharma announces departure of jasbir seehra phd chief scientific officer acceleron via fiercebiotech november     press release acceleron pharma appoints glenn batchelder as ceo and adds richard f pops to board of directors acceleron via businesswire june     flanagan michael july   acceleron value in the wallflower biocentury   carroll john november   emerging drug developer acceleron fiercebiotech   heuser stephen july   superbuff cattle may hold key to treating muscular diseases boston globe   celgene commits b to acceleron fiercebiotech february     a b accelerons celgene deal worth almost b boston business journal february     weintraub arlene  august  acceleron gets  million in partnership deal with celgene xconomy   huggett brady december  burning bright nature biotechnology   pp –   lawrence stacy september   bayer commercial vet heads to acceleron as it preps for phiii celgene data fiercebiotech  retrieved from httpsenwikipediaorgwindexphptitleacceleronpharmaoldid categories pharmaceutical companies established in companies based in bostonpharmaceutical companies of the united statescompanies listed on nasdaq establishments in massachusettshealth care companies based in massachusetts navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages deutsch edit links this page was last edited on  june  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view creative commons — attributionsharealike  unported — cc bysa  skip to content menu help us build a vibrant collaborative global commons donate now creative commons creative commons license deed attributionsharealike  unported cc bysa  this is a humanreadable summary of and not a substitute for the license disclaimer you are free to share — copy and redistribute the material in any medium or format adapt — remix transform and build upon the material for any purpose even commercially the licensor cannot revoke these freedoms as long as you follow the license terms under the following terms attribution — you must give appropriate credit provide a link to the license and indicate if changes were made you may do so in any reasonable manner but not in any way that suggests the licensor endorses you or your use attribute this work sharealike — if you remix transform or build upon the material you must distribute your contributions under the same license as the original no additional restrictions — you may not apply legal terms or technological measures that legally restrict others from doing anything the license permits notices you do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation no warranties are given the license may not give you all of the permissions necessary for your intended use for example other rights such as publicity privacy or moral rights may limit how you use the material learn more about cc licensing or use the license for your own material this content is freely available under simple legal terms because of creative commons a nonprofit that survives on donations if you love this content and love that its free for everyone please consider a donation to support our work make a donation this page is available in the following languages castellano castellano españa català dansk deutsch english esperanto français galego hrvatski indonesia italiano latviski lietuvių melayu nederlands norsk polski português português br română slovenščina suomeksi svenska türkçe íslenska česky ελληνικά беларуская русский українська العربية پارسی  語   한국어 this content is freely available under simple legal terms because of creative commons a nonprofit that survives on donations if you love this content and love that its free for everyone please consider a donation to support our work when you share everyone wins contribute today to creative commons     disclaimer this deed highlights only some of the key features and terms of the actual license it is not a license and has no legal value you should carefully review all of the terms and conditions of the actual license before using the licensed material creative commons is not a law firm and does not provide legal services distributing displaying or linking to this deed or the license that it summarizes does not create a lawyerclient or any other relationship what does attribute this work mean the page you came from contained embedded licensing metadata including how the creator wishes to be attributed for reuse you can use the html here to cite the work doing so will also include metadata on your page so that others can find the original work as well the applicable mediation rules will be designated in the copyright notice published with the work or if none then in the request for mediation unless otherwise designated in a copyright notice attached to the work the uncitral arbitration rules apply to any arbitration more info if supplied you must provide the name of the creator and attribution parties a copyright notice a license notice a disclaimer notice and a link to the material cc licenses prior to version  also require you to provide the title of the material if supplied and may have other slight differences more info in  you must indicate if you modified the material and retain an indication of previous modifications in  and earlier license versions the indication of changes is only required if you create a derivative marking guide more info you may also use a license listed as compatible at httpscreativecommonsorgcompatiblelicenses more info a commercial use is one primarily intended for commercial advantage or monetary compensation more info merely changing the format never creates a derivative more info the license prohibits application of effective technological measures defined with reference to article  of the wipo copyright treaty more info the rights of users under exceptions and limitations such as fair use and fair dealing are not affected by the cc licenses more info you may need to get additional permissions before using the material as you intend more info accelerating drug discovery to transform patients lives   accelerating drug discovery to transform patients’ livesluspatercept designed to treat chronic anemias in rare blood diseasesadvancing global phase  studies in mds  betathalassemiapreviousnext our companyguided by deep scientific expertise  driven by a passion to deliverwe are focused on harnessing the power of the tgfbeta superfamily the targetrich biology behind the body’s remarkable capacity for cellular growth and repair our insights and protein engineering capabilities enable us to design first and bestinclass candidates for serious and rare diseases our lead product luspatercept is being evaluated in two global phase  studies in partnership with celgene to treat chronic anemia in mds and betathalassemia we are also advancing clinical programs for neuromuscular diseasesread more we are building a rich pipeline based on leadership in tgfbeta biology hematologyluspatercepthematologyluspaterceptpreclinicalphase phase phase  myelodysplastic syndromesmyelodysplastic syndromesmedalist studymedalist studylongterm extension studylongterm ext stfirstline lowerrisk mds cohortsst line lowerrisk mdsbetathalassemiabetathalassemiabelieve studybelieve studylongterm extension studylongterm ext st ntd ph  study plannedntd ph  plannedmyelofibrosismyelofibrosisph  study plannedph  planned sotaterceptpreclinicalphase phase phase  myelofibrosissotatercept myelofibrosis investigatorsponsored studyinvestsponsored st neuromuscularacepreclinicalphase phase phase  neuromuscularace fsh muscular dystrophyfsh muscular dystrophy part  ongoingpt  ongoing charcotmarietooth diseasecharcotmarietooth disease ph  study plannedph  planned acceleronnews   acceleron pharma  wikipedia acceleron pharma from wikipedia the free encyclopedia jump to navigation search acceleron pharma inc traded as nasdaq xlrn industry biotechnology founded   headquarters cambridge massachusetts united states key people habib dable ceo steve ertel coo matt sherman cmo kevin mclaughlin cfo  website acceleronpharmacom acceleron pharma inc is a public american clinical stage biopharmaceutical company based in boston massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta tgfβ superfamily of proteins which play fundamental roles in the growth and repair of cells and tissues such as red blood cells muscle bone and blood vessels pipelineedit acceleron has four drugs in clinical trials and one in preclinical development luspatercept ace for anemia  sotatercept ace for kidney disease dalantercept ace for kidney cancer ace for muscular disorders ace historyedit the company was formed in june  in cambridge massachusetts as a delaware corporation the original name was phoenix pharma the founders were scientists jasbir seehra tom maniatis mark ptashne wylie vale and scientific advisor joan massague and business people and investors john knopf and christoph westphal of polaris venture partners who served as founding ceo the company was founded to discover and develop drugs based on the scientific discoveries of the scientific founders in the field of growth factors and transforming growth factors in the fields of metabolic disorders like obesity diabetes osteoporosis and musclewasting conditions the company began with a seed round from polaris of  and then had a series a venture capital investment of  million that it used to open its first laboratory in december  glenn batchelder was appointed president and ceo in june  it started its first clinical trial in june  the product was ace which eventually was named sotatercept a protein therapeutic that was an activin type  receptor antagonist intended to treat bone loss ace was a chimeric protein created by fusing the binding portion of the activin type  receptor to part of an antibody the resulting protein binds to activin and prevents it from acting a muscular belgian blue cow knopf took over as ceo in  he became known for showing pictures of a belgian blue cow to potential inventors as a way of illustrating the companys products potential to develop muscle in  acceleron and celgene started a partnership to jointly develop and market ace in which celgene paid acceleron  million up front and bought  million of acceleron stock and agreed to buy  million more in stock if acceleron went public and agreed to pay up to  million in milestones in a separate deal done at the same time celgene acquired an option to license three products in accelerons pipeline directed to cancer and cancerrelated bone loss in  acceleron extended its their partnership with celgene to include ace a development candidate for anemia celgene paid  million upfront with potential downstream payments of  million in milestones and royalties over  the company held its initial public offering in september  at that time the company had three protein therapeutic candidates being studied in  phase  clinical trials including sotatercept and luspatercept ace which promoted red blood cell production and were being tested as potential treatments for anemia in people with thalassemia and myelodysplastic syndromes mds its other candidate was dalantercept ace an angiogenesis inhibitor as a potential cancer drug in september  knopf retired and the company hired habib dable as ceo at that time the companys lead product luspatercept was in phase iii testing for mds and betathalassemia referencesedit  httpwwwacceleronpharmacomourcompanymanagement  httpwwwacceleronpharmacomproducts  a b luspatercept adisinsight retrieved  february    a b sotatercept adisinsight retrieved  february    a b dalantercept adisinsight retrieved  february    ace  adisinsight retrieved  february    ace  product profile biocentury retrieved  february    a b c cooke philip ed  local clusters and global networks regional knowledge economies google ebook new horizons in regional science united kingdom edward elgar publishing p  isbn    a b mclellan dennis january   wylie w vale jr dies at  researcher helped discover stress hormone los angeles times   a b c d acceleron s acceleron via sec edgar august     acceleron pharma developing drugs to treat musculoskeletal and metabolic disorders secures  million in series a funding nasdaqxlrn investoracceleronpharmacom february     press release acceleron pharma announces departure of jasbir seehra phd chief scientific officer acceleron via fiercebiotech november     press release acceleron pharma appoints glenn batchelder as ceo and adds richard f pops to board of directors acceleron via businesswire june     flanagan michael july   acceleron value in the wallflower biocentury   carroll john november   emerging drug developer acceleron fiercebiotech   heuser stephen july   superbuff cattle may hold key to treating muscular diseases boston globe   celgene commits b to acceleron fiercebiotech february     a b accelerons celgene deal worth almost b boston business journal february     weintraub arlene  august  acceleron gets  million in partnership deal with celgene xconomy   huggett brady december  burning bright nature biotechnology   pp –   lawrence stacy september   bayer commercial vet heads to acceleron as it preps for phiii celgene data fiercebiotech  retrieved from httpsenwikipediaorgwindexphptitleacceleronpharmaoldid categories pharmaceutical companies established in companies based in bostonpharmaceutical companies of the united statescompanies listed on nasdaq establishments in massachusettshealth care companies based in massachusetts navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages deutsch edit links this page was last edited on  june  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view acceleron pharma  linkedin linkedin main content starts below acceleron pharma  wikipedia acceleron pharma from wikipedia the free encyclopedia jump to navigation search acceleron pharma inc traded as nasdaq xlrn industry biotechnology founded   headquarters cambridge massachusetts united states key people habib dable ceo steve ertel coo matt sherman cmo kevin mclaughlin cfo  website acceleronpharmacom acceleron pharma inc is a public american clinical stage biopharmaceutical company based in boston massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta tgfβ superfamily of proteins which play fundamental roles in the growth and repair of cells and tissues such as red blood cells muscle bone and blood vessels pipelineedit acceleron has four drugs in clinical trials and one in preclinical development luspatercept ace for anemia  sotatercept ace for kidney disease dalantercept ace for kidney cancer ace for muscular disorders ace historyedit the company was formed in june  in cambridge massachusetts as a delaware corporation the original name was phoenix pharma the founders were scientists jasbir seehra tom maniatis mark ptashne wylie vale and scientific advisor joan massague and business people and investors john knopf and christoph westphal of polaris venture partners who served as founding ceo the company was founded to discover and develop drugs based on the scientific discoveries of the scientific founders in the field of growth factors and transforming growth factors in the fields of metabolic disorders like obesity diabetes osteoporosis and musclewasting conditions the company began with a seed round from polaris of  and then had a series a venture capital investment of  million that it used to open its first laboratory in december  glenn batchelder was appointed president and ceo in june  it started its first clinical trial in june  the product was ace which eventually was named sotatercept a protein therapeutic that was an activin type  receptor antagonist intended to treat bone loss ace was a chimeric protein created by fusing the binding portion of the activin type  receptor to part of an antibody the resulting protein binds to activin and prevents it from acting a muscular belgian blue cow knopf took over as ceo in  he became known for showing pictures of a belgian blue cow to potential inventors as a way of illustrating the companys products potential to develop muscle in  acceleron and celgene started a partnership to jointly develop and market ace in which celgene paid acceleron  million up front and bought  million of acceleron stock and agreed to buy  million more in stock if acceleron went public and agreed to pay up to  million in milestones in a separate deal done at the same time celgene acquired an option to license three products in accelerons pipeline directed to cancer and cancerrelated bone loss in  acceleron extended its their partnership with celgene to include ace a development candidate for anemia celgene paid  million upfront with potential downstream payments of  million in milestones and royalties over  the company held its initial public offering in september  at that time the company had three protein therapeutic candidates being studied in  phase  clinical trials including sotatercept and luspatercept ace which promoted red blood cell production and were being tested as potential treatments for anemia in people with thalassemia and myelodysplastic syndromes mds its other candidate was dalantercept ace an angiogenesis inhibitor as a potential cancer drug in september  knopf retired and the company hired habib dable as ceo at that time the companys lead product luspatercept was in phase iii testing for mds and betathalassemia referencesedit  httpwwwacceleronpharmacomourcompanymanagement  httpwwwacceleronpharmacomproducts  a b luspatercept adisinsight retrieved  february    a b sotatercept adisinsight retrieved  february    a b dalantercept adisinsight retrieved  february    ace  adisinsight retrieved  february    ace  product profile biocentury retrieved  february    a b c cooke philip ed  local clusters and global networks regional knowledge economies google ebook new horizons in regional science united kingdom edward elgar publishing p  isbn    a b mclellan dennis january   wylie w vale jr dies at  researcher helped discover stress hormone los angeles times   a b c d acceleron s acceleron via sec edgar august     acceleron pharma developing drugs to treat musculoskeletal and metabolic disorders secures  million in series a funding nasdaqxlrn investoracceleronpharmacom february     press release acceleron pharma announces departure of jasbir seehra phd chief scientific officer acceleron via fiercebiotech november     press release acceleron pharma appoints glenn batchelder as ceo and adds richard f pops to board of directors acceleron via businesswire june     flanagan michael july   acceleron value in the wallflower biocentury   carroll john november   emerging drug developer acceleron fiercebiotech   heuser stephen july   superbuff cattle may hold key to treating muscular diseases boston globe   celgene commits b to acceleron fiercebiotech february     a b accelerons celgene deal worth almost b boston business journal february     weintraub arlene  august  acceleron gets  million in partnership deal with celgene xconomy   huggett brady december  burning bright nature biotechnology   pp –   lawrence stacy september   bayer commercial vet heads to acceleron as it preps for phiii celgene data fiercebiotech  retrieved from httpsenwikipediaorgwindexphptitleacceleronpharmaoldid categories pharmaceutical companies established in companies based in bostonpharmaceutical companies of the united statescompanies listed on nasdaq establishments in massachusettshealth care companies based in massachusetts navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages deutsch edit links this page was last edited on  june  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view